Allison Whitten AstraZeneca reports mixed Phase 3 results across oncology and rare disease AstraZeneca reported mixed late-stage clinical results, with its Claudin 18.2-targeting antibody-drug conjugate sonesitatug vedotin meeting its primary endpoint in patients with previously treated advanced gastric cancer, while rare disease therapy Ultomiris missed the primary endpoint in a Phase 3 trial for thrombotic microangiopathy following haematopoietic stem cell transplantation (HSCT-TMA)
Sikiric defends the compound, pointing to decades of animal and cell work reporting broad healing effects and few side effects, and rejecting suggestions that BPC-157 is not a naturally occurring substance.
The speed of improvement after a B12 injection can vary from person to person
FIGURE 10 Notably, activators of SIRT1, such as metformin, have demonstrated the ability to inhibit Th17 cell differentiation and downregulate IL-17A and RORt levels by promoting STAT3 deacetylation ( In summary, our study primarily investigated the beneficial effects of GHK-Cu in UC, using a DSS-induced colitis mouse model and an in vitro co-culture system, suggesting that GHK-Cu may exert anti-inflammatory properties and its role in facilitating the repair of UC by regulating SIRT1/STAT3 signaling pathway
Real-world Response Timeline across BPC-157 Injectable Protocols Days 1 to 5: Most users reported little to no change, while some noted mild injection-site redness
I didn't know it was genetic, but apparently it is